Literature DB >> 15542132

Medicare reform and your practice: what you need to know.

John Christopher Lyne1.   

Abstract

Reimbursements for Medicare Part B physician-administered medications have been cut and will be further reduced in the years to come. Physician groups have supported the prescription benefit within the Medicare reform package. However, physician and patient advocacy groups alike are concerned about how other portions of the legislation will change the administration of Medicare Part B-covered drugs in the office setting. This article explores the payment changes built into the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, what the proponents and opposition have been saying, and how these changes will impact the practice of urology and patients with prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15542132     DOI: 10.1016/j.urology.2004.08.061

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  2 in total

Review 1.  Pharmacoeconomics of available treatment options for metastatic prostate cancer.

Authors:  Steven B Zeliadt; David F Penson
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

2.  Private Practice Administrative Costs Influenced by Insurance Payer Mix.

Authors:  Jorge M Luna; Paul W Thurman; Margaret Wolfe; Daniel Yagoda; Edward Reed; William D Figg
Journal:  J Oncol Pract       Date:  2009-11       Impact factor: 3.840

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.